Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China-Reference-Cited by-同舟云学术

Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China

Published:2023-07 Issue:5 Volume:7 Page:100192
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Zhou Hu,Zhou Jianfeng,Wu Depei,Ma Liping,Du Xin,Niu Ting,Yang Renchi,Liu Jing,Zhang Feng,Shi Qingzhi,Wang Xiuli,Jing Hongmei,Li Junmin,Wang Xin,Cui Zhongguang,Zhou Zeping,Hou Ming,Shao Zonghong,Jin Jie,Li Wenqian,Ren Hanyun,Hu Jianda,Shen Jianliang,Liu Li,Zeng Yun,Zhou Jin,Liu Xin,Shen Yunfeng,Ding Kai,Taira Tadaaki,Cai Huacong,Zhao Yongqiang

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. International consensus report on the investigation and management of primary immune thrombocytopenia;Provan;Blood,2010

2. Current management of primary immune thrombocytopenia;Provan;Adv Ther,2015

3. American Society of Hematology 2019 guidelines for immune thrombocytopenia;Neunert;Blood Adv,2019

4. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea;Lee;Thromb Res,2017

5. A review of romiplostim mechanism of action and clinical applicability;Bussel;Drug Des Devel Ther,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China;Intractable & Rare Diseases Research;2024-08-31